https://ht.digitalsenda.com/highlight-therapeutics-announces-completion-of-enrollment-for-phase-2b-study-of-bo-112-in-large-underserved-basal-cell-carcinoma-population/ 2026-01-28T14:42:43+00:00 https://ht.digitalsenda.com/buenavista-cierra-una-ronda-de-15-millones-un-nuevo-impulso-para-seguir-avanzando-en-inmunoterapia/ 2025-10-16T10:29:48+00:00 https://ht.digitalsenda.com/bo-112-debuta-en-esmo-io-2019/ 2025-10-15T13:20:06+00:00 https://ht.digitalsenda.com/nuevo-ensayo-clinico-con-bo-112-en-melanoma-avanzado/ 2025-10-15T13:19:57+00:00 https://ht.digitalsenda.com/msd-y-bioncotech-nuevo-ensayo-clinico-en-metastasis-hepaticas/ 2025-10-15T13:19:45+00:00 https://ht.digitalsenda.com/promising-results-from-our-latest-immuno-oncology-trial-point-to-stronger-and-more-durable-patient-responses/ 2025-10-12T15:49:51+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-7/ 2025-10-09T17:05:09+00:00 https://ht.digitalsenda.com/the-odyssey-of-three-women-and-bo-112-the-molecule-that-tricks-cancer/ 2025-08-14T09:35:51+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-6/ 2025-02-17T13:37:27+00:00 https://ht.digitalsenda.com/call-for-general-ordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-2/ 2024-09-11T12:34:08+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-5/ 2024-09-11T12:33:33+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l/ 2024-09-11T06:55:41+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-4/ 2024-09-11T06:53:06+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-3/ 2024-09-11T06:52:31+00:00 https://ht.digitalsenda.com/highlight-therapeutics-announces-follow-up-results-from-phase-2b-study-of-bo-112-anti-pd1-in-confirmed-anti-pd1-progressor-melanoma-patients-at-aacr/ 2024-09-11T06:51:56+00:00 https://ht.digitalsenda.com/highlight-therapeutics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting-2022/ 2024-09-11T06:51:12+00:00 https://ht.digitalsenda.com/highlight-therapeutics-cima-announce-positive-results-from-pre-clinical-study-combining-bo112-sting-agonist-published-in-journal-for-immunotherapy-of-cancer/ 2024-09-11T06:50:35+00:00 https://ht.digitalsenda.com/highlight-announces-positive-preliminary-results-from-phase-2b-study-of-bo-112anti-pd1-in-confirmed-anti-pd1-progressor-melanoma-patients-at-sitc/ 2024-09-11T06:50:04+00:00 https://ht.digitalsenda.com/highlight-to-present-data-from-phase-2-immunotherapy-studies-of-liver-metastases-and-melanoma-data/ 2024-09-11T06:49:29+00:00 https://ht.digitalsenda.com/call-for-general-extraordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l-2/ 2024-09-11T06:48:51+00:00 https://ht.digitalsenda.com/highlight-therapeutics-and-pivotal-work-together-on-melanoma-therapy-and-launch-a-phase-iia-trial-to-examine-bo-112-efficacy-and-safety/ 2024-09-11T06:48:19+00:00 https://ht.digitalsenda.com/second-collaboration-with-msd-to-evaluate-combination-of-bo-112-and-keytruda/ 2024-09-11T06:46:37+00:00 https://ht.digitalsenda.com/highlight-therapeutics-announces-first-patient-dosed-in-phase-iia-study-in-liver-metastasis/ 2024-09-11T06:45:58+00:00 https://ht.digitalsenda.com/call-for-general-ordinary-shareholders-meeting-of-the-company-highlight-therapeutics-s-l/ 2024-09-11T06:45:10+00:00 https://ht.digitalsenda.com/highlight-therapeutics-strengthens-board-and-advisory-board/ 2024-09-11T06:43:55+00:00 https://ht.digitalsenda.com/highlight-therapeutics-announces-name-change-from-bioncotech-and-launch-of-new-website/ 2024-09-11T06:42:41+00:00 https://ht.digitalsenda.com/highlight-therapeutics-commentary-published-in-the-european-biotechnology-magazine/ 2024-09-11T06:41:48+00:00 https://ht.digitalsenda.com/highlight-therapeutics-published-in-the-european-biopharmaceutical-review/ 2024-09-11T06:41:08+00:00 https://ht.digitalsenda.com/highlight-therapeutics-selected-for-cancer-research-uk-project/ 2024-09-11T06:40:21+00:00 https://ht.digitalsenda.com/phase-i-bo-112-data-presented-at-esmo-immuno-oncology-congress-2019/ 2024-09-11T06:39:29+00:00 https://ht.digitalsenda.com/oncology-clinical-trial-collaboration-with-msd/ 2024-09-11T06:38:02+00:00